Osteoporosis, Bisphosphonates, and Dental Care: What Patients Should Know

Osteoporosis treatment and dental care intersect at a single, serious complication: medication-related osteonecrosis of the jaw. The condition is uncommon but consequential, and the risk is strongly shaped by decisions made long before a tooth becomes a problem, which is why patients and clinicia...

Osteoporosis treatment and dental care intersect at a single, serious complication: medication-related osteonecrosis of the jaw. The condition is uncommon but consequential, and the risk is strongly shaped by decisions made long before a tooth becomes a problem, which is why patients and clinicians need the same information.

Why Bone Health Matters to Teeth

Osteoporosis and the Jaw

Osteoporosis reduces bone mineral density throughout the skeleton, including the mandible and maxilla, and the reduction is measurable on dental radiographs. A study in the Journal of the American Dental Association in 2012 reported that panoramic indices of mandibular cortical width correlated with hip and spine bone density.

Medications Involved

Antiresorptive drugs include oral and intravenous bisphosphonates and denosumab, while antiangiogenic agents used in oncology form a separate but overlapping risk category. A study in the Journal of Bone and Mineral Research in 2015 described the mechanisms by which these agents suppress bone turnover in the jaw.

What MRONJ Is

Definition and Features

Medication-related osteonecrosis of the jaw is defined as exposed bone or bone that can be probed through a fistula in the maxillofacial region, persisting for more than eight weeks in a patient with current or previous antiresorptive treatment and no history of radiotherapy to the area.

Typical Presentation

Pain, swelling, a non-healing extraction socket, discharge or altered sensation may all be presenting features. A study in the Journal of Oral and Maxillofacial Surgery in 2014 found that the mandible was affected roughly twice as often as the maxilla.

Staging

Staging from zero to three guides management, from observation in early stages to resection in advanced disease. A study in the Journal of the American Dental Association in 2014 reported that most oral bisphosphonate-associated cases presented at an early stage.

Risk by Drug and Route

Oral Bisphosphonates

The estimated incidence of osteonecrosis in patients taking oral bisphosphonates for osteoporosis is low, generally reported as between 0.01 and 0.1 per cent, and the risk rises with duration of use beyond four years. Khosla and colleagues, writing in the Journal of the American Dental Association in 2015, estimated an incidence of approximately 0.1 per cent after four years of oral therapy.

Intravenous Bisphosphonates

Patients receiving intravenous agents for malignancy carry a substantially higher risk, with estimates in the range of 1 to 3 per cent after extraction. A study in the Journal of Clinical Oncology in 2011 reported that cumulative dose was the strongest predictor of risk in this group.

Denosumab and Other Agents

Denosumab carries a risk comparable to intravenous bisphosphonates in oncology dosing and, unlike bisphosphonates, its effect declines within months of cessation. A study in the Journal of Bone and Mineral Research in 2017 noted that the shorter half-life has practical implications for surgical timing.

Before Dental Treatment

Informed Assessment

Clinicians should record the drug name, dose, route, duration and date of initiation for every patient with a relevant history. A study in the Journal of the American Dental Association in 2016 found that documentation of antiresorptive therapy was incomplete in a substantial proportion of dental records.

Timing of Extractions

Whenever possible, extractions and other surgical procedures should be completed before antiresorptive therapy begins or during the early months of treatment. A study in the Journal of Oral and Maxillofacial Surgery in 2013 reported lower complication rates when surgery preceded the initiation of therapy.

Minimally Invasive Approaches

Where extraction is unavoidable, atraumatic technique, primary closure and antibiotic cover are widely used, although evidence for the last of these remains limited. A systematic review in the Journal of Cranio-Maxillofacial Surgery in 2018 found no consistent benefit from routine antibiotic prophylaxis.

Drug Holidays

What Guidance Says

Guidance from professional bodies suggests that a drug holiday is generally unnecessary for patients who have taken oral bisphosphonates for less than four years without other risk factors. Khosla and colleagues, in the Journal of the American Dental Association in 2015, found insufficient evidence to support interruption of therapy in this group.

Why the Debate Continues

Bisphosphonates persist in bone for years after cessation, so interrupting therapy does not immediately restore turnover. A study in Bone in 2014 reported that measurable drug effects persisted for up to ten years after stopping oral therapy, which limits the logic of a short holiday.

Prevention Is the Priority

Oral Hygiene

Maintaining excellent oral hygiene is the most effective way to avoid the extractions that trigger osteonecrosis, and preventive care should begin at the time osteoporosis treatment starts. A study in the Journal of the American Dental Association in 2018 reported that patients enrolled in a preventive dental programme required fewer extractions.

Regular Dental Review

Dental review every six months allows early treatment of decay and periodontal disease while they remain non-surgical problems. A powered brush such as the BrushO with a pressure sensor and a two minute timer supports consistent plaque control at the gingival margin, which reduces both caries and periodontitis risk in patients who cannot afford an extraction.

Communication Between Clinicians

The prescribing physician and the dentist should share information before any surgical procedure, and the decision to interrupt therapy should be made jointly. A study in Osteoporosis International in 2015 found that joint protocols reduced the incidence of complications in patients starting antiresorptive therapy.

Recognising Problems Early

Symptoms That Matter

Persistent pain, a non-healing socket, exposed bone, loose teeth or altered sensation in the lip or chin should prompt an urgent dental review. A study in the Journal of Oral and Maxillofacial Surgery in 2015 found that early presentation was associated with better outcomes and lower rates of surgical intervention.

What Patients Should Report

Patients should tell every clinician which antiresorptive drug they take and when it began, including drugs prescribed for cancer rather than for osteoporosis. A study in Supportive Care in Cancer in 2016 reported that patients frequently could not name their medication, which delayed appropriate dental planning.

Living Well With Osteoporosis

Calcium, Vitamin D and Exercise

Adequate calcium and vitamin D intake and weight-bearing exercise remain the foundation of bone health alongside medication. A study in the New England Journal of Medicine in 2016 emphasised that fracture prevention requires treatment adherence rather than intermittent use.

Managing Dry Mouth

Some patients on osteoporosis regimens report dry mouth, which increases caries risk and complicates hygiene. Sugar-free chewing gum, frequent sips of water and fluoride toothpaste help maintain the oral environment.

Conclusion

Medication-related osteonecrosis of the jaw is rare in patients taking oral bisphosphonates for osteoporosis, with an estimated incidence around 0.1 per cent after four years, but the consequences when it occurs are serious. Prevention through meticulous oral hygiene, regular review and completion of surgery before therapy remains far more effective than any intervention after the event.

（内容由AI生成，仅供参考）